-
公开(公告)号:UY39395A
公开(公告)日:2022-03-31
申请号:UY39395
申请日:2021-08-26
Applicant: VERTEX PHARMA
Inventor: MAXWELL BRAD D , COCHRAN JOHN E , AHN JUN MYUN , ANGLE SAMANTHA , CAO JINGRONG , COME JON H , DAKIN LESLIE A , DOLGIKH ELENA , NANTHAKUMAR SUGANTHINI S , O’DOWD HARDWIN , OLSEN JESSICA HOWARD , SENTER TIMOTHY J , SHIMIZU AKIRA JOSEPH , STONE STEVEN DAVID , WANG HAOXUAN , BRODNEY MICHAEL AARON
IPC: A61K31/35 , A61K31/381 , A61K31/438 , A61P13/12 , A61P35/00 , C07D491/20 , C07D495/14 , C07D515/20
Abstract: La presente invención proporciona al menos una entidad elegida de los Compuestos de la Fórmula I, un tautómero del mismo, un derivado deuterado de ese compuesto o tautómero, y una sal farmacéuticamente aceptable de cualquiera de los anteriores, composiciones que comprenden los mismos, y métodos para usar los mismos, incluyendo los usos en el tratamiento de enfermedades mediadas por APOL1, incluyendo cáncer pancreático, glomeruloesclerosis segmentaria focal (FSGS), y/o enfermedad renal no diabética (NDKD).
-
公开(公告)号:BR112021011564A2
公开(公告)日:2021-08-31
申请号:BR112021011564
申请日:2019-12-17
Applicant: VERTEX PHARMA
Inventor: MEDEK ALES , FORTIER ANNE , LEDFORD BRIAN , SAYEGH CAMIL , ELAINE B KRUEGER , WITKOS FAITH , DENIS FRANCOIS , CAO JINGRONG , JON H COME , HU KAN-NIAN , GAGNON KEVIN , LESLIE A DAKIN , HAMEL MARTINE , BRODNEY MICHAEL , SHRESTHA MUNA , NICOLAS OLIVIER , ROSE PETER , SUGANTHINI S NANTHAKUMAR , WANG TIANSHENG , TIMOTHY J SENTER , WARREN A DORSCH , SHI YI
IPC: C07D403/12 , A61K31/4025 , A61P13/12
Abstract: inibidores de apol1 e métodos de uso dos mesmos. trata-se de pelo menos uma entidade escolhida dentre os compostos de fórmula (i), formas de estado sólido dos mesmos, composições que compreendem os mesmos e métodos para usar os mesmos, incluindo o uso no tratamento de glomeruloesclerose segmentar focal (gesf) e/ou doença renal não diabética (ndkd).
-
公开(公告)号:ES2842399T3
公开(公告)日:2021-07-14
申请号:ES17187529
申请日:2010-12-21
Applicant: VERTEX PHARMA
Inventor: ARONOV ALEX , COME JON H , DAVIES ROBERT J , PIERCE ALBERT CHARLES , COLLIER PHILIP N , GREY RONALD LEE , O'DOWD HARWIN , HENDERSON JAMES A , KRUEGER ELAINE B , LE TIRAN AMAUD , LIAO YUSHENG , MESSERSMITH DAVID , WANG JIAN , NANTHAKUMAR SUGANTHINI S , CAO JINGRONG , BANDARAGE UPUL KEERTHI , GRILLOT ANNE-LAURE
IPC: C07D401/04 , A61K31/352 , A61K31/424 , A61K31/429 , A61P9/00 , A61P29/00 , A61P37/00 , C07D401/14 , C07D405/14 , C07D417/14 , C07D471/04 , C07D471/20 , C07D491/20
Abstract: Compuesto que presenta la fórmula: **(Ver fórmula)** o una sal farmacéuticamente aceptable del mismo, en la que: X1 es CH o N; R1 se selecciona entre un anillo fenilo o piridinilo, en el que el anillo fenilo o piridinilo está opcionalmente sustituido con 1 o 2 apariciones independientes de R1a; R1a es cloro, flúor, alifático C1-6, cicloalifático C3-6, -CN, -C(O)R1b, -C(O)N(R1b)2, -C(O)O(R1b) u -OR1b, en los que cada uno de dicho alifático o cicloalifático se sustituye opcionalmente con hasta 3 apariciones de JR; cada JR es independientemente flúor, oxo, -CN, -C(O)R1b, -C(O)N(R1b)2, -C(O)O(R1b), -N(R1b)2, -N(R1b)C(O)R1b, OR1b o un heteroarilo o heterociclilo de 5 miembros que tiene hasta 3 átomos seleccionados entre nitrógeno, oxígeno o azufre; cada R1b se selecciona, independientemente de entre hidrógeno, alifático C1-4 o cicloalifático C3-6; R2 es hidrógeno, F, Cl, CF3 o CH3; B es N; C es CRC, en donde Rc es hidrógeno, flúor, cloro, alifático C1-3, CF3, -OCF3 u -Oalifático C1-2 y D es CRD, en donde RD es flúor, cloro, alifático C1-3, CF3, -OCF3 u -Oalifático C1-2.
-
公开(公告)号:CA2785499C
公开(公告)日:2017-05-02
申请号:CA2785499
申请日:2010-12-21
Applicant: VERTEX PHARMA
Inventor: ARONOV ALEX , COME JON H , DAVIES ROBERT J , PIERCE ALBERT CHARLES , WANG JIAN , NANTHAKUMAR SUGANTHINI S , CAO JINGRONG , BANDARAGE UPUL KEERTHI , KRUEGER ELAINE B , LE TIRAN ARNAUD , LIAO YUSHENG , MESSERSMITH DAVID , COLLIER PHILIP N , GREY RONALD LEE JR , O'DOWD HARDWIN , HENDERSON JAMES A , GRILLOT ANNE-LAURE
IPC: C07D401/04 , A61K31/352 , A61K31/424 , A61K31/429 , A61P9/00 , A61P29/00 , A61P37/00 , C07D401/14 , C07D405/14 , C07D417/14 , C07D471/04 , C07D471/20 , C07D491/20
Abstract: The present invention relates to compounds having the formula: (see formula I) useful as inhibitors of PI3K, particularly of PI3K.gamma.. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
-
公开(公告)号:CA2988306A1
公开(公告)日:2016-12-08
申请号:CA2988306
申请日:2016-06-03
Applicant: VERTEX PHARMA
Inventor: DAVIES ROBERT J , CAO JINGRONG , COCKERILL MEGHAN ELISE , COLLIER PHILIP NOEL , DENINNO MICHAEL PAUL , DOYLE ELISABETH , FRANTZ JAMES DANIEL , GAO HUAI , GOLDMAN BRIAN ANTHONY , GREY RONALD LEE , GRILLOT ANNE-LAURE , GU WENXIN , HENDERSON JAMES A , KRAUSS RAUL EDUARDO , KOLPAK ADRIANNE LYNN , LIAO YUSHENG , MAGAVI SANJAY SHIVAYOGI , MALTAIS FRANCOIS , MESSERSMITH DAVID , PIERCE ALBERT CHARLES , PEROLA EMANUELE , RYU ELIZABETH JIN-SUN , SYKEN JOSHUA , WANG JIAN
IPC: A61K31/4196 , A61P25/28 , C07D249/14 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/14 , C07D405/12 , C07D405/14
Abstract: The invention relates to triazole compounds of formula I and I' or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases: The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention, methods of using the compositions and kits thereof in the treatment of various demyelinating and neurodegenerative diseases, including multiple sclerosis.
-
公开(公告)号:ZA200810791B
公开(公告)日:2010-03-31
申请号:ZA200810791
申请日:2007-06-13
Applicant: VERTEX PHARMA
Inventor: GUTIERREZ COREY , TERMIN ANDREAS , HADIDA-RUAH SARA , JOSHI PRAMOD , BERGERON DANIELE , YOO SANGHEE , BINCH HAYLEY , COME JON , NANTHAKUMAR SUGANTHI , CAO JINGRONG
IPC: A61K20100101 , C07D20100101
-
公开(公告)号:AU2006202623B2
公开(公告)日:2009-05-14
申请号:AU2006202623
申请日:2006-06-20
Applicant: VERTEX PHARMA
Inventor: HALE MICHAEL , CAO JINGRONG , STRAUB JUDY , ARONOV ALEX , GREEN JEREMY , MALTAIS FRANCOIS , TANG QING
IPC: C07D403/04 , A61K31/506 , A61P35/00 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14
-
公开(公告)号:DE60041763D1
公开(公告)日:2009-04-23
申请号:DE60041763
申请日:2000-04-21
Applicant: VERTEX PHARMA
Inventor: SALITURO FRANCESCO GERALD , BEMIS GUY W , WILKE SUSANNE , GREEN JEREMY , CAO JINGRONG , GAO HUAI , HARRINGTON EDMUND MARTIN
IPC: C07D209/40 , A61K31/395 , A61P43/00 , C07D401/06 , C07D401/14 , C07D403/06 , C07D405/06 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/06 , C07D417/06 , C07D417/14 , C07F7/08
-
公开(公告)号:AT425142T
公开(公告)日:2009-03-15
申请号:AT00926272
申请日:2000-04-21
Applicant: VERTEX PHARMA
Inventor: SALITURO FRANCESCO , BEMIS GUY , WILKE SUSANNE , GREEN JEREMY , CAO JINGRONG , GAO HUAI , HARRINGTON EDMUND
IPC: C07D209/40 , A61K31/395 , A61P43/00 , C07D401/06 , C07D401/14 , C07D403/06 , C07D405/06 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/06 , C07D417/06 , C07D417/14 , C07F7/08
-
公开(公告)号:CA2369504C
公开(公告)日:2009-01-06
申请号:CA2369504
申请日:2001-02-05
Applicant: VERTEX PHARMA
Inventor: BEMIS GUY , CAO JINGRONG , MULLICAN MICHAEL , XIE XIAOLING , GREEN JEREMY , STRAUB JUDITH , MASHALL ROBERT , JANETKA JAMES , MALTAIS FRANCOIS , BAKER CHRISTOPHER , HALE MICHAEL , TANG QING
IPC: A61B17/00 , C07D403/04 , A61F2/02 , A61K31/4155 , A61K31/4178 , A61K31/433 , A61K31/437 , A61K31/4439 , A61K31/454 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/5377 , A61K31/551 , A61K45/00 , A61L27/00 , A61L27/28 , A61L31/08 , A61P1/00 , A61P1/16 , A61P1/18 , A61P3/10 , A61P5/00 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P13/00 , A61P13/10 , A61P13/12 , A61P15/00 , A61P17/00 , A61P17/06 , A61P19/00 , A61P21/00 , A61P25/00 , A61P25/28 , A61P29/00 , A61P31/00 , A61P31/12 , A61P35/00 , A61P35/02 , A61P37/00 , A61P37/02 , A61P37/04 , A61P37/06 , A61P37/08 , A61P43/00 , C07D231/38 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04
Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: (I) where R1-4, Q, and T are described in the specification. Th e compounds are useful for treating disease states in mammals that are alleviated by a prote in kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, an d cardiovascular disease.
-
-
-
-
-
-
-
-
-